E Is OxiGene The Cheapest Biotech On The Nasdaq?

Summary points:
 
-OxiGene is the ideal buying opportunity in biotech: very limited downside risk vs huge upside potential.
-The downside is very limited because the stock now trades at net cash (!), with 3 years runway.
-The upside is huge given the rich pipeline and multiple near-term catalysts lined up.
-After positive Phase II end results on both safety and efficacy, OxiGene’s lead drug against ovarian cancer will probably advance to Phase III within months.
-Peer biotech stocks are valued much, much higher.

1 2 3 4
View single page >> |

Disclosure: Long OXGN. Please do your due diligence before investing.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Dick Kaplan 5 years ago Member's comment

$OXGN looks very promising, thanks.

Dan Jackson 5 years ago Member's comment

Excellent article, but "cheap" is a relative firm. Personally, I consider it to be fairly priced:

charts.stocktwits.com/.../original_34689474.jpg

Danny Straus 5 years ago Member's comment

I disagree, after reading the above this looks like a distinct opportunity.